Floatz Rating
CC40/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04126200CT.gov Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT06160609CT.gov Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gsk 3174998 (this asset) | GlaxoSmithKline | P1/2 | CC · 40 |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Prednisone | GlaxoSmithKline | P4 | BB |
| Adriamycin | GlaxoSmithKline | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Janssen Research & Development, LLC | P4 | BB |
| Thalidomide | Institute of Hematology & Blood Diseases Hospital, China | P4 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Gsk 3174998
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P1 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gsk 3174998 in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gsk-3174998-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →